{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T17:31:17Z","timestamp":1784309477892,"version":"3.55.0"},"reference-count":36,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Foundation Against Cancer (Brussels, Belgium)","award":["2019-108"],"award-info":[{"award-number":["2019-108"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>(1) Background: Haematological malignancies (HMs) represent a heterogeneous group of mostly rare cancers that differ in pathophysiology, incidence, and outcome. (2) Methods: Our study aims to understand the epidemiological situation and trends of 24 main types of HMs in Belgium over a 15-year period, with a focus on the impact of age. Age-standardised incidence, average annual percentage change (AAPC), 5- and 10-year relative survival (RS) and RS trends were estimated for all HMs (N = 94,415) diagnosed between 2004 and 2018. (3) Results: Incidence rates of HM increased, mainly in the 70+ age group (AAPC: 3%). RS varied by age and HM type. For each HM type, outcome decreased with age. The greatest decrease with age in 5-year RS is observed for aggressive HM, acute myeloid leukaemia (AML), acute lymphoblastic leukaemia, and Burkitt lymphoma, from 67%, 90%, and 97% below 20 years, to 2%, 12%, and 16% above 80 years of age, respectively. The moderate improvement in 5-year RS over the 2004\u20132018 period for all HMs, of +5 percentage point (pp), masks highly heterogenous outcomes by HM type and age group. The most impressive improvements are observed in the 80+ group: +45, +33, +28, and +16 pp for Hodgkin lymphoma, immunoproliferative disorders, follicular lymphoma, and chronic myeloid leukaemia, respectively. (4) Conclusions: The increasing incidence and survival over the 2004\u20132018 period are likely explained by diagnostic and therapeutic innovations, which have spread to populations not targeted by clinical trials, especially older adults. This real-world population-based study highlights entities that need significant improvement, such as AML.<\/jats:p>","DOI":"10.3390\/cancers15174388","type":"journal-article","created":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T02:43:20Z","timestamp":1693795400000},"page":"4388","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Epidemiological Trends of Haematological Malignancies in Belgium 2004\u20132018: Older Patients Show the Greatest Improvement in Survival"],"prefix":"10.3390","volume":"15","author":[{"given":"Kris","family":"Henau","sequence":"first","affiliation":[{"name":"Belgian Cancer Registry, Rue Royale 215, 1210 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Tambuyzer","sequence":"additional","affiliation":[{"name":"Belgian Cancer Registry, Rue Royale 215, 1210 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8604-8097","authenticated-orcid":false,"given":"Bart","family":"Van Gool","sequence":"additional","affiliation":[{"name":"Belgian Cancer Registry, Rue Royale 215, 1210 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liesbet","family":"Van Eycken","sequence":"additional","affiliation":[{"name":"Belgian Cancer Registry, Rue Royale 215, 1210 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne A.","family":"Poirel","sequence":"additional","affiliation":[{"name":"Belgian Cancer Registry, Rue Royale 215, 1210 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,1]]},"reference":[{"key":"ref_1","unstructured":"(2023, July 01). Belgian Cancer Registry. Available online: https:\/\/kankerregister.org\/default.aspx?lang=EN."},{"key":"ref_2","unstructured":"Swerdlow, S.H., Campo, E., Harris, L.N., Jaffe, E.S., Pileri, S.A., Stein, H., and Thiele, J. (2017). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press. [Revised 4th ed.]."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1016\/j.ejca.2011.08.008","article-title":"RARECARE working group. Rare cancers are not so rare: The rare cancer burden in Europe","volume":"47","author":"Gatta","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"ref_4","unstructured":"Jaffe, E.S., Harris, N.L., Vardiman, J.W., and Stein, H. (2001). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press. [3rd ed.]."},{"key":"ref_5","unstructured":"Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., and Stein, H. (2008). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press. [4th ed.]."},{"key":"ref_6","unstructured":"HAEMACARE Working Group (2010). Manual for coding and reporting haematological malignancies. Tumori, 96, i-A32."},{"key":"ref_7","unstructured":"Le Guyader-Peyrou, S., Defossez, G., Dantony, E., Mounier, M., Cornet, E., Uhry, Z., Cowppli-Bony, A., Maynadi\u00e9, M., Troussard, X., and Delafosse, P. (2019). National Estimates of Cancer Incidence and Mortality in Metropolitan France between 1990 and 2018 a Study Based on Francim Network of Cancer Registries Volume 2\u2014Hematological Malignancies, Francim Network. Study from the Cancer Registries of the Francim Network."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/bjh.12659","article-title":"Differences in incidence and trends of haematological malignancies in Japan and the United States","volume":"164","author":"Chihara","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.medcli.2021.09.035","article-title":"Estimates of the incidence of hematological neoplasms in Spain, 2021: Study of the Spanish Network of Cancer Registries (REDECAN). Estimaciones de la incidencia de las neoplasias hematol\u00f3gicas en Espa\u00f1a, 2021: Estudio de la Red Espa\u00f1ola de Registros de C\u00e1ncer (REDECAN)","volume":"158","author":"Sanvisens","year":"2022","journal-title":"Med. Clin."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"101841","DOI":"10.1016\/j.canep.2020.101841","article-title":"Population-based survival of lymphoid neoplasms: Twenty years of epidemiological data in the Girona province, Spain","volume":"69","author":"Villavicencio","year":"2020","journal-title":"Cancer Epidemiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/bjc.2011.450","article-title":"Incidence of haematological malignancy by sub-type: A report from the Haematological Malignancy Research Network","volume":"105","author":"Smith","year":"2011","journal-title":"Br. J. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.canep.2014.10.009","article-title":"Regional variation in incidence for smoking and alcohol related cancers in Belgium","volume":"39","author":"Henau","year":"2015","journal-title":"Cancer Epidemiol."},{"key":"ref_13","unstructured":"Tambuyzer, T., Henau, K., Calay, F., Van Gool, B., Silversmit, G., and Van Eycken, L. (2020). Cancer Burden in Belgium 2004\u20132017, Belgian Cancer Registry."},{"key":"ref_14","unstructured":"Ferlay, J., Burkhard, C., Whelan, S., and Parkin, D. (2005). Check and Conversion Programs for Cancer Registries, IARC. Technical Report No 42."},{"key":"ref_15","unstructured":"Henau, K., Francart, J., Silversmit, G., Vandendael, T., Pieters, G., Xicluna, J., Rosskamp, M., De Schutter, H., Slabbaert, M., and Van Damme, N. (2015). Cancer Burden in Belgium 2004\u20132013, Belgian Cancer Registry."},{"key":"ref_16","first-page":"101","article-title":"The relative survival rate: A statistical methodology","volume":"6","author":"Ederer","year":"1961","journal-title":"Natl. Cancer Inst. Monogr."},{"key":"ref_17","unstructured":"Noone, A., Howlader, N., Krapcho, M., Miller, D., Brest, A., Yu, M., Ruhl, J., Tatalovich, Z., Mariotto, A., and Lewis, D. (2023, July 01). SEER Cancer Statistics Review, 1975\u20132015, National Cancer Institute. Bethesda, MD. Based on November 2017 SEER Data Submission, Posted to the SEER Web Site, April 2018. [Online], Available online: https:\/\/seer.cancer.gov\/csr\/1975_2015\/."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00432-015-2017-z","article-title":"Are epidemiological data on lymphoma incidence comparable? Results from an application of the coding recommendations of WHO, InterLymph, ENCR and SEER to a cancer registry dataset","volume":"142","author":"Adzersen","year":"2016","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/bs.ircmb.2021.06.004","article-title":"Targets in MPNs and potential therapeutics","volume":"366","author":"Levy","year":"2022","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/joim.13019","article-title":"Incidence of myeloproliferative neoplasms\u2014Trends by subgroup and age in a population-based study in Sweden","volume":"287","author":"Hultcrantz","year":"2020","journal-title":"J. Intern. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1080\/10428194.2021.1992756","article-title":"Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States","volume":"63","author":"Verstovsek","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1002\/cam4.1461","article-title":"Incidence and survival of hematological cancers among adults ages \u226575 years","volume":"7","author":"Fisher","year":"2018","journal-title":"Cancer Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1080\/10428194.2022.2053529","article-title":"Incidence and survival estimates for patients with myelodysplastic syndrome in the early 21st century: No evidence of improvement over time","volume":"63","author":"Pulte","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3109\/0284186X.2015.1115124","article-title":"Trends in hematological cancer in the elderly in Denmark, 1980\u20132012","volume":"55","author":"Ocias","year":"2016","journal-title":"Acta Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Mounier, M., Romain, G., Callanan, M., Alla, A.D., Boussari, O., Maynadi\u00e9, M., Colonna, M., and Jooste, V. (2021). Flexible Modeling of Net Survival and Cure by AML Subtype and Age: A French Population-Based Study from FRANCIM. J. Clin. Med., 10.","DOI":"10.3390\/jcm10081657"},{"key":"ref_27","unstructured":"Monnereau, A., Dantony, E., Mounier, M., Troussard, X., Maynadie, M., Cornet, E., Orazio, S., Lafay, L., Lecoffre, C., and Remontet, L. (2021, January 16\u201318). Is survival of major lymphoid malignancies subtypes still increasing in the French population?. Proceedings of the ENCR 2021 Meeting Abstract Poster, Virtual Event."},{"key":"ref_28","unstructured":"Mounier, M., Uhry, Z., Monnereau, A., Maynadie, M., Troussard, X., Cornet, E., Orazio, S., De Brauer, C., De Maria, F., and Bossard, N. (2021, January 12\u201314). Survival of myeloid malignancies in France from 1989 to 2018 in general population: What\u2019s new?. Proceedings of the GRELL 2021 Meeting Abstract Poster, Virtual Event."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s41408-022-00728-z","article-title":"Survival trends in hematological malignancies in the Nordic countries through 50 years","volume":"12","author":"Hemminki","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/bjh.18083","article-title":"British Society for Haematology. Guideline for the first-line management of Classical Hodgkin Lymphoma\u2014A British Society for Haematology guideline","volume":"197","author":"Follows","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N. Eng. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s12094-020-02541-1","article-title":"Trends of incidence, mortality and survival of multiple myeloma in Spain. A twenty-three-year population-based study","volume":"23","year":"2021","journal-title":"Clin. Transl. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"824704","DOI":"10.3389\/fonc.2022.824704","article-title":"Real-World Estimation of First- and Second-Line Treatments for Diffuse Large B-Cell Lymphoma Using Health Insurance Data: A Belgian Population-Based Study","volume":"12","author":"Daneels","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1038\/bjc.2015.94","article-title":"Lymphoma incidence, survival and prevalence 2004-2014: Sub-type analyses from the UK\u2019s Haematological Malignancy Research Network","volume":"112","author":"Smith","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Guevara, M., Molinuevo, A., Salmer\u00f3n, D., Marcos-Gragera, R., Carulla, M., Chirlaque, M.D., Rodr\u00edguez Camblor, M., Alem\u00e1n, A., Rojas, D., and Vizca\u00edno Batll\u00e9s, A. (2022). Cancer Survival in Adults in Spain: A Population-Based Study of the Spanish Network of Cancer Registries (REDECAN). Cancers, 14.","DOI":"10.3390\/cancers14102441"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.leukres.2013.12.018","article-title":"The relevance of a geriatric assessment for elderly patients with a haematological malignancy\u2014A systematic review","volume":"38","author":"Hamaker","year":"2014","journal-title":"Leuk. Res."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/17\/4388\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:45:13Z","timestamp":1760129113000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/17\/4388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":36,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["cancers15174388"],"URL":"https:\/\/doi.org\/10.3390\/cancers15174388","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,1]]}}}